Results 21 to 30 of about 20,735 (212)
Journal of Pure and Applied Microbiology, 2022 ChAdOx1 nCoV-19 Vaccine (Covishield) has shown good efficacy data but the presence of non responders to the vaccine and the duration of protection conferred by the vaccine has not been clearly documented.
P. Sneka +2 more
doaj +1 more source
Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine [PDF]
BMJ Case Reports, 2021 A 50-year-old Indian woman presented with acute dysphasia, left upper limb numbness and thrombocytopenia 12 days after receiving the ChAdOx1 nCoV-19 vaccine (AstraZeneca/Vaxzevria). MRI of the brain was unremarkable. Microangiopathic haemolytic anaemia with thrombocytopenia was noted on her peripheral blood film.
Hui Ping Lee +2 more
openaire +2 more sources
The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
Vaccines, 2021 Coronavirus Disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the global challenge. Reaching global herd immunity will help end the COVID-19 pandemic.
Tzu-Chuan Ho +8 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2022 Introduction Due to the vaccine’s short supply and the efficacy of a single dose of the ChAdOx1 (AZD1222) vaccine, many governments delayed the interval between prime and boost dose from 4 to 8–12 weeks.
Kriangkrai Tawinprai +8 more
doaj +1 more source
Vaccines, 2023 Immunogenicity data on the mRNA SARS-CoV-2 vaccine booster after completing a primary series vaccination, other than the mRNA vaccine, in patients with autoimmune rheumatic diseases (ARDs) is scarce.
Porntip Intapiboon +5 more
doaj +1 more source
Identification of antigens presented by MHC for vaccines against tuberculosis [PDF]
, 2020 Mycobacterium tuberculosis (M.tb) is responsible for more deaths globally than any other pathogen. The only available vaccine, bacillus Calmette-Guérin (BCG), has variable efficacy throughout the world. A more effective vaccine is urgently needed.
Bettencourt, Paulo +14 more
core +1 more source
Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination [PDF]
Case Reports in Critical Care, 2022 Vaccine-induced thrombotic thrombocytopenia is an uncommon complication of COVID-19 vaccines using adenovirus mRNA carriers and has been associated with thrombosis of the cerebral venous sinuses and portal system. We report a case of a 69-year-old woman admitted to the intensive care unit due to stroke caused by thrombosis of the right carotid artery 9
Giorgio Berlot +5 more
openaire +4 more sources
Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines: [Preprint] [PDF]
, 2021 Vector-based SARS-CoV-2 vaccines have been associated with vaccine-induced thrombosis with thrombocytopenia syndrome (VITT/TTS), but the causative factors are still unresolved.
Beer, Martin +16 more
core +1 more source
Scientific Reports, 2022 Scarce data have been reported about cellular immunity and longevity for different COVID-19 vaccination schedules. We carried out a prospective study enrolling 709 healthcare workers receiving two doses of mRNA-1273, BNT162b2, ChAdOx1, ChAdOx1/BNT162b2 ...
Leire Fernández-Ciriza +7 more
doaj +1 more source
Vaccines, 2022 We determined the levels of neutralizing antibodies against the SARS-CoV-2 ancestral strain, Delta and Omicron variants of concern (VOCs), in 125 healthcare workers who received CoronaVac as their primary vaccination and later received either a single ...
Rome Buathong +15 more
doaj +1 more source